Ultrasonographic Evaluation of Morphological and Functional Characteristics of Intercostal Muscles in Stroke Patients and Their Relationship With Clinical Parameters
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Stroke frequently leads to respiratory muscle dysfunction due to impaired central motor control. Although diaphragm involvement after stroke has been extensively investigated, there is limited evidence regarding the morphological and functional characteristics of extra-diaphragmatic inspiratory muscles, particularly the parasternal intercostal muscles.
The primary objective of this study is to evaluate parasternal intercostal muscle morphology and contractility in individuals with stroke using ultrasonography. Parasternal intercostal muscle thickness will be measured at end-tidal expiration and maximal inspiration, and intercostal muscle thickening fraction (ICTf) will be calculated as an indicator of muscle contractility. Measurements will be obtained bilaterally, allowing comparison between the hemiplegic and non-hemiplegic sides.
In addition, diaphragm thickness and diaphragm thickening fraction will be assessed using ultrasonography. Respiratory muscle strength will be evaluated by maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements according to ATS/ERS recommendations. Pulmonary function tests including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC ratio will also be performed.
Clinical outcomes including motor impairment, balance, functional independence, and stroke-specific quality of life will be assessed using the Fugl-Meyer Assessment, Berg Balance Scale, Functional Independence Measure (FIM), and Stroke-Specific Quality of Life Scale (SS-QoL), respectively.
A healthy control group matched for age, sex, and body mass index will be included to establish reference values for parasternal intercostal muscle ultrasonographic measurements and to allow comparative analyses between stroke patients and healthy individuals.
The study is designed as a single-center, controlled cross-sectional observational study. A minimum of 40 individuals with stroke and 25 healthy volunteers will be enrolled. Associations between ultrasonographic respiratory muscle measurements and clinical parameters will be analyzed to improve understanding of respiratory muscle involvement after stroke and its relationship with functional outcomes.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ozge Kenis Coskun
- E-mail: ozgekenis@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Oguzhan Kasimoglu
- Numéro de téléphone: +905448911835
- E-mail: kasimogluoguzhan@gmail.com
Lieux d'étude
-
-
Maltepe
-
Istanbul, Maltepe, Turquie (Türkiye), 34854
- Marmara Üniversitesi Tıp Fakültesi
-
Contact:
- Secretary General Secretary
- Numéro de téléphone: +90 2166254545
- E-mail: ozgekenis@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria (Stroke Group):
- Age between 18 and 75 years.
- History of ischemic or hemorrhagic stroke.
- Ability to understand and comply with study procedures.
- Provision of written informed consent.
Exclusion Criteria (Stroke Group):
- Presence of acute or chronic pulmonary disease.
- History of thoracic or abdominal surgery.
- Presence of another neuromuscular disorder.
- Aphasia or cognitive impairment preventing participation in assessments.
- Active malignancy.
Inclusion Criteria (Healthy Control Group):
- Age between 18 and 75 years.
- Willingness to participate in the study.
- Provision of written informed consent.
Exclusion Criteria (Healthy Control Group):
- History of stroke or other neurological disorders.
- History of chronic respiratory disease (e.g., COPD, asthma).
- Chest wall deformity.
- Presence of systemic diseases that may affect muscle function.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Group 1: Stroke Patients
Adults aged 18-75 years with a history of ischemic or hemorrhagic stroke who meet the study eligibility criteria.
A minimum of 40 participants will be enrolled in this group.
|
|
Group 2: Healthy Controls
Age-eligible healthy volunteers without a history of stroke, neurological disease, chronic respiratory disease, chest wall deformity, or systemic disease affecting muscle function.
A minimum of 25 participants will be enrolled in this group.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Parasternal Intercostal Muscle Thickening Fraction (ICTf)
Délai: Baseline
|
Ultrasonographic assessment of parasternal intercostal muscle contractility.
Thickening fraction will be calculated as: (Inspiratory Thickness - Expiratory Thickness) / Expiratory Thickness × 100.
Higher values indicate greater inspiratory muscle contractile activity.
Comparison will be performed between the hemiplegic and non-hemiplegic sides.
|
Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Parasternal Intercostal Muscle Thickness
Délai: Baseline
|
Ultrasonography will be used to examine the structure and function of the muscle and to measure muscle thickness at the end of inspiration and expiration.
|
Baseline
|
|
Intercostal Muscle Asymmetry Index
Délai: Baseline
|
Intercostal Muscle Asymmetry Index (AI) is a normalized measure of side-to-side differences in parasternal intercostal muscle contractility.
The asymmetry index is calculated using the formula |TF₁ - TF₂| / [(TF₁ + TF₂)/2] × 100, where TF represents the intercostal muscle thickening fraction measured by ultrasonography.
Higher values indicate greater asymmetry between the two sides, whereas lower values indicate more symmetrical intercostal muscle function.
|
Baseline
|
|
Relative Hemiplegic Deficit
Délai: Baseline
|
Relative Hemiplegic Deficit is a measure of the reduction in parasternal intercostal muscle contractility on the hemiplegic side relative to the non-hemiplegic side in individuals with stroke.
It is calculated using the formula [(TFnon-hemiplegic - TFhemiplegic) / TFnon-hemiplegic] × 100, where TF represents the intercostal muscle thickening fraction measured by ultrasonography.
Higher values indicate a greater functional deficit of the hemiplegic side, while lower values indicate more preserved intercostal muscle function.
|
Baseline
|
|
Diaphragm Thickening Fraction
Délai: Baseline
|
Diaphragm contractility assessed by ultrasonography.
Thickening fraction is calculated as [(Thickness at maximal inspiration - Thickness at end-expiration) / Thickness at end-expiration] × 100.
Higher values indicate greater diaphragm contractile function.
|
Baseline
|
|
Maximal Inspiratory Pressure (MIP)
Délai: Baseline
|
Maximum inspiratory pressure (MIP) is a measurement that evaluates the strength of the inspiratory muscles.
This test measures the negative pressure created when a person breathes in at maximum effort.
MIP assesses the strength of respiratory muscles, such as the diaphragm and intercostal muscles, and is used to diagnose conditions characterized by respiratory muscle weakness.
|
Baseline
|
|
Maximal Expiratory Pressure (MEP)
Délai: Baseline
|
Maximum expiratory pressure (MEP) is a measurement that evaluates the strength of the expiratory muscles.
This test measures the positive pressure generated when a person exhales with maximum effort.
MEP assesses the strength of expiratory muscles, including the abdominal and internal intercostal muscles, and is commonly used to evaluate respiratory muscle function and identify conditions associated with expiratory muscle weakness.
Higher values indicate greater expiratory muscle strength.
|
Baseline
|
|
Fugl-Meyer Assessment Score
Délai: Baseline
|
The Fugl-Meyer Assessment (FMA) is a stroke-specific impairment scale used to evaluate motor recovery after stroke.
The motor domain score ranges from 0 to 100 points, with higher scores indicating better motor function and less motor impairment.
|
Baseline
|
|
Berg Balance Scale Score
Délai: Baseline
|
The Berg Balance Scale (BBS) consists of 14 tasks assessing static and dynamic balance.
Scores range from 0 to 56 points.
Higher scores indicate better balance performance and lower fall risk, whereas lower scores indicate greater balance impairment.
|
Baseline
|
|
Functional Independence Measure (FIM) Score
Délai: Baseline
|
The Functional Independence Measure assesses the level of disability and functional independence in activities of daily living.
Total scores range from 18 to 126 points.
Higher scores indicate greater independence and lower levels of assistance required.
|
Baseline
|
|
Stroke-Specific Quality of Life (SS-QoL) Score
Délai: Baseline
|
Stroke-Specific Quality of Life Scale (SS-QoL) is used to assess the life expectancy of a stroke survivor.
It is specifically designed for individuals who have had a stroke.
Both personal and psychosocial effects are assessed collectively.
Scores range from 49-245.
Higher scores indicate better functioning.
|
Baseline
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MarmaraU-FTR-OK-4
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .